ASCO: Radioimmunotherapy + gemcitabine shows promise for pancreatic cancer

Links shared publicly online about this topic.

1,423
total visits

ASCO: Radioimmunotherapy + gemcitabine shows promise for pancreatic cancer

The results of an ongoing phase I/II study for treating advanced pancreatic cancer with a combination therapy of Immunomedics' antibody, clivatuzumab tetraxetan, (90Y-hPAM4) and anticancer drug gemcitabine, which demonstrated therapeutic activity at two 90Y dose levels with minimal hematologic toxicity, was presented with positive findings at the seventh annual Gastrointestinal Cancers Symposium in Orlando, Fla. this week.

View full resource at healthimaging.com

Tags: Pancreatic Disease, Cancer, Cancer Medication, Pancreatic Cancer, Drug, Gemzar